Hans / Pixabay
The News:
Alnylam Pharmaceuticals Inc.’s (Cambridge MA) RNAi-based drug that targets a rare genetic disease cleared a key study, in a breakthrough for the new class of m… Read More
Patisiran, which is intended for the rare and progressive disease hereditary ATTR amyloidosis with polyneuropathy, is “the first ever positive Phase 3 results for an RNAi therapeutic… Read More
Credit Suisse bumped up the target of Alnylam Pharmaceuticals (NDAQ:ALNY) to $90.00 stating a potential upside of 0.27%.
On 5/15/2017, Chardan Capital released a statement for Alnylam Pharm… Read More
Lo scorso anno la Fda ha approvato il Patisiran, il primo farmaco specificamente autorizzato per il trattamento di una malattia rara e mortale chiamata amiloidosi ereditaria da transtiretina… Read More
The CPT® 2019 Professional Edition, page 721 contains the following information and direction for CPT® codes to be used for the Administration of Chemotherapy:“Chemotherapy ad… Read More
A recent article published by the well-known medical and health information website Xconomy pointed out that many new drugs are expected to be approved to enter the market before t… Read More
In the latest issue of the JMC journal, a review article, entitled “A Decade of FDA-Approved Drugs (2010-2019): Trends and Future Directions”, was published, which analyzed and s… Read More
What is nanomedicine
Nanomaterials refer to materials with a spatial size of 1-100 nm (see Figure 1). Nanomedicine refers to various types of nanomaterials that can play a role in the tre… Read More
The newly added Familial Amyloid Polyneuropathy Therapeutics market research report by Value Market Research disclose all the important information associated with the market such as v… Read More
We discuss how silicon coatings can improve the performance of instrumentation and process equipment in life science applications.
Coatings for the Building Blocks of Life
In this blog… Read More
1. Chemistry Modification
Chemical modification represents one of the most effective approaches to enhance oligonucleotide drug delivery. Modification of the nucleic acid backbone, the ri… Read More
With the continuous development of molecular biology technology, the relationship between gene mutations and diseases has gained more and more in-depth understanding. Nucleic acids have attr… Read More
Drug Modification
Drug modification involves altering the chemical structure of the drug itself (such as functional groups, amino acids or nucleic acid skeletons) and coupling the drug wi… Read More
Credited as a pioneering RNA interference (RNAi) therapeutics company, Alnylam Pharmaceuticals is taking Pfizer and Moderna to court, claiming that the companies’ use of the lipid nano… Read More
Oligonucleotides are short synthetic DNA or RNA polymers, which modulate gene expression through Watson-Crick base pairing with targeted nucleic acids. Oligonucleotides regulate gene express… Read More
In a press release on August 4, 2022, Bluebird Bio (NASDAQ: BLUE) announced the appointment of Thomas J. Klima, 50, as its Chief Commercial and Operating Officer, starting August 8, 2022. Si… Read More
Target knockdown and safety results support continued clinical development
Regeneron and Alnylam intend to initiate a Phase 2 study in late 2022
Detailed results to be presented at an upco… Read More
The stock market is struggling, yet scores of biotech stocks are surging like it’s a new bull market, all the way from top-rated Catalyst Pharmaceuticals, through such heavy hitters… Read More
Why oligonucleotide drugs?
Synthetic oligonucleotides are the key factor in almost all molecular biological methodologies. They are used in PCR, reverse transcription, sequencing, gene ed… Read More
Small nucleic acid-based drugs, namely oligonucleotide drugs, are short-chain nucleic acids consisting of dozens of nucleotides in series. At present, most oligonucleotide drugs are obtained… Read More
The ‘Global Transthyretin Amyloidosis Treatment Market Report and Forecast 2023-2031’ by Expert Market Research gives an extensive outlook of the global transthyretin amyloidosis… Read More
It is possible for transthyretin amyloid cardiomyopathy (ATTR-CM, also called cardiac ATTR amyloidosis) to be reversed with antibody treatment, as suggested by rare cases of patients who h… Read More
FDA advisors conceded on Wednesday that the benefit-risk balance of patisiran (Onpattro) technically checks out in wild-type or hereditary transthyretin amyloid cardiomyopathy (ATTR-CM, al… Read More
“You have no idea how much it pains me to conclude that extended pleurectomy/decortication — an operation that we have been offering for over 70 years — has been asso… Read More
CLEVELAND — In a surprise Monday morning move, the FDA declined to expand the indication for anti-amyloid agent patisiran (Onpattro) in treating wild-type or hereditary transthyret… Read More
Compared with viral vectors, non-viral delivery vectors are easier to scale up and have the ability to solve the most critical safety issues. Thanks to the LNP-mRNA vaccine that came to the… Read More
As an important drug modality, the development of oligonucleotides will continue to expand in the coming years. Oligonucleotide drugs are a class of therapeutic agents composed of short nucl… Read More
New York, New York--(Newsfile Corp. - October 23, 2023) - Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (NASDAQ:… Read More